Tamoxifen and anastrozole as a sequencing strategy: A randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group

Journal of Clinical Oncology

Volumn 30, Issue 7, 2012, Pages 722-728

  Dubsky, Peter C ^a   Jakesz, Raimund ^a   Fitzal, Florian ^a   Singer, Christian F ^a   Rudas, Margaretha ^a   Bartsch, Rupert ^a   Steger, Günther G ^a   Gnant, Michael ^a   Filipcic, Lidija ^b   Stierer, Michael ^c   Sevelda, Paul ^d   Mlineritsch, Brigitte ^e   Greil, Richard ^e   Pöstlberger, Sabine ^f   Samonigg, Hellmut ^g   Stöger, Herbert ^g   Luschin Ebengreuth, Gero ^g   Kwasny, Werner ^h   Haider, Karin ^h   Taucher, Susanne ⁱ   Tausch, Christoph ^j   more..

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Austrian Breast and Colorectal Cancer Study Group Trial Centre   (Austria)

^c Hanusch Medical Centre   (Austria)

^d UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF SALZBURG   (Austria)

^f Hospital Barmherzige Schwestern Linz   (Austria)

^g MEDICAL UNIVERSITY OF GRAZ   (Austria)

^h Hospital Wiener Neustadt   (Austria)

ⁱ INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^j Brust Zentrum   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; ASTHENIA; BONE PAIN; BREAST CANCER; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CONTROLLED STUDY; DIARRHEA; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; HAIR LOSS; HIGH RISK POPULATION; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; NAUSEA; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOEMBOLISM; TOXICITY; VAGINA BLEEDING; VAGINA DISCHARGE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; AUSTRIA; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; PROSPECTIVE STUDIES; SURVIVAL RATE; TAMOXIFEN; TRIAZOLES;

EID: 84857508799     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.36.8993     Document Type: Article

References (24)

1. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: Interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet 1:257-261, 1983
2. Forbes JF, Cuzick J, Buzdar A, et al: Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45-53, 2008
3. Mouridsen H, Giobbie-Hurder A, Goldhirsch A, et al: Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 361:766-776, 2009
4. Dowsett M, Cuzick J, Ingle J, et al: Metaanalysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518, 2010
5. Jonat W, Gnant M, Boccardo F, et al: Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: A meta-analysis. Lancet Oncol 7:991-996, 2006 (Pubitemid 44804137)
6. Kaufmann M, Jonat W, Hilfrich J, et al: Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: The ARNO 95 study. J Clin Oncol 25:2664-2670, 2007 (Pubitemid 47123171)
7. Boccardo F, Rubagotti A, Guglielmini P, et al: Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17:vii10-vii14, 2006 (suppl 7)
8. Jakesz R, Jonat W, Gnant M, et al: Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455- 462, 2005
9. van de Velde CJ, Rea D, Seynaeve C, et al: Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): A randomised phase 3 trial. Lancet 377:321-331
10. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
11. Hudis CA, Barlow WE, Costantino JP, et al: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 25:2127-2132, 2007 (Pubitemid 46972801)
12. Rea D, Hasenburg A, Seynaeve C, et al: Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: The TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormonesensitive early breast cancer. Presented at the 32nd San Antonio Breast Cancer Symposium, San Antonio, TX, December 10, 2009 (abstr 11)
13. Potter R, Gnant M, Kwasny W, et al: Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer. Int J Radiat Oncol Biol Phys 68:334-340, 2007 (Pubitemid 46694171)
14. Thurlimann B, Keshaviah A, Coates AS, et al: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005 (Pubitemid 43016814)
15. Coombes RC, Kilburn LS, Snowdon CF, et al: Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 369:559-570, 2007
16. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
17. Goss PE, Ingle JN, Martino S, et al: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA. 17. J Natl Cancer Inst 97:1262-1271, 2005 (Pubitemid 41535367)
18. Jakesz R, Greil R, Gnant M, et al: Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: Results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99:1845- 1853, 2007
19. Burstein HJ, Prestrud AA, Seidenfeld J, et al: American Society of Clinical Oncology clinical practice guideline: Update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796, 2010
20. Filipits M, Rudas M, Jakesz R, et al: A new molecular predictor of distant recurrence in ERpositive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 17:6012-6020, 2011
21. Pfeiler G, Königsberg R, Fesl C, et al: Impact of body mass index on endocrine therapy in premenopausal breast cancer patients: An analysis of the ABCSG-12 trial. J Clin Oncol 29:2653-2659, 2011
22. Sestak I, Distler W, Forbes JF, et al: Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J Clin Oncol 28:3411-3415, 2010
23. Schroth W, Goetz MP, Hamann U, et al: Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302:1429- 1436, 2009
24. Rageth JC, Bronz L, Granberg S: Tamoxifen and the endometrium: Monitoring and evaluation of endometrial changes [in German]. Arch Gynecol Obstet 256:S122-S127, 1995 (suppl)